Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months

Journal of Bone and Mineral Research

Volumn 23, Issue 8, 2008, Pages 1304-1308

  Bolland, Mark J ^a   Grey, Andrew B ^a   Horne, Anne M ^a   Briggs, Simon E ^a,b   Thomas, Mark G ^a,b   Ellis Pegler, Rod B ^a,b   Gallon, Karen E ^a   Gamble, Greg D ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

BMD; Bone turnover; HIV; Osteoporosis; Zoledronate

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTIRETROVIRUS AGENT; BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; TIME FACTORS;

EID: 47849083833     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080312     Document Type: Article

References (13)

1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
2. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 357:1799-1809.
3. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR 2007 Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: A randomized controlled trial. J Clin Endocrinol Metab 92:1283-1288.
4. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661.
5. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Guide S, Wu W, Mangood A, Russell RG, Ebetino FH 2006 Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617-627.
6. Borba VZ, Paz-Filho G, Kulak CA, Seibel MJ, Bilezikian JP 2007 Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int J Clin Pract 61:1058-1062.
7. Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE 2007 Prolonged efficacy of a single dose of the bisphosphonate zoledronic Acid. Clin Cancer Res 13:5406-5410.
8. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258.
9. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
10. Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890-899.
11. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301.
12. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D 2006 Osteonecrosis of the jaw: More research needed. J Bone Miner Res 21:1503-1505.
13. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T 2004 Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35:224-230.